19 papers in the library · 730 citations · publishing 2019-2026
JAMA Psychiatry October 21, 2026 Ellen Bradley, Parker Kelley, Balázs Szigeti et al.
This nonrandomized clinical trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease and mood dysfunction.
Preventive Medicine Reports September 2026 Pedro J. Teixeira, Rakesh Jain, Andrew Penn et al. correction
[This corrects the article DOI: 10.1016/j.pmedr.2025.103161.].
Journal of Psychedelic Studies April 15, 2026 Hannah Whitmore, Brian T Anderson, Elena Flowers et al.
Abstract Background and Aims Mental health challenges such as depression, anxiety, and existential distress are common among individuals with terminal illness. Preliminary evidence suggests that death acceptance may protect against these issues, but there is limited research on the role of psychedelic-assisted therapy in fostering death acceptance. This scoping review aims to explore the...
Preventive Medicine Reports August 1, 2025 Pedro J. Teixeira, Rakesh Jain, Andrew Penn et al. 1 citation
Psychedelics have been increasingly studied for their potential to influence mental health and well-being, yet their relationship with broader health behaviors remains underexplored. This study examined associations between lifetime psychedelic use and health-related behaviors, including substance use, dietary habits, and impulsive tendencies. Using an extensive cross-sectional online survey,...
Neuropsychopharmacology April 9, 2025 Ellen Bradley, Kimberly Sakai, Gisele Fernandes-Osterhold et al. 23 citations
Mood dysfunction is highly prevalent in Parkinson's disease (PD), a main predictor of functional decline, and difficult to treat-novel interventions are critically needed. Psilocybin shows early promise for treating depression and anxiety, but its potential in PD is unknown, as safety concerns have excluded people with neurodegenerative disease from previous trials. In this open-label pilot...
Journal of Hospice and Palliative Nursing April 1, 2025 Megan Miller, Molly Meyers, Annona Martin et al. 3 citations
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence suggests possible utility of PAT for addressing psychosocial-spiritual-existential concerns, yet gaps remain in understanding findings related to PAT's role in palliative care. This rapid review aims to synthesize current literature on applications of...
Journal of Hospice and Palliative Nursing April 1, 2025 Megan Miller, Molly Meyers, Annona Martin et al.
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence suggests possible utility of PAT for addressing psychosocial-spiritual-existential concerns, yet gaps remain in understanding findings related to PAT's role in palliative care. This rapid review aims to synthesize current literature on applications of...
Psychedelic Medicine December 13, 2023 Andrew Penn, Rachel Yehuda 7 citations
The reemergence of psychedelic medicines as clinical treatments has generated considerable interest in both professional and popular arenas. Although evidence is promising for psychedelic-assisted therapy (PAT), there is much that is not yet known and needs to be researched so as to understand how to safely and effectively utilize PAT in clinical populations and to most effectively deploy PAT...
Psychedelic Medicine September 1, 2023 Zachary Herrmann, Adam W. Levin, Steven P Cole et al. 9 citations
Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a...
JAMA August 31, 2023 Charles L. Raison, Gerard Sanacora, Joshua Woolley et al. 493 citations
Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were...
Journal of Midwifery & Women's Health May 6, 2022 Cindy A. Stein, Andrew Penn, Stephanie Van Hope et al. 9 citations
The research and use of psychedelic medicines to treat common mental health disorders has increased substantially in the past 2 decades. At the same time, knowledge is relatively uncommon among midwives regarding (1) the relative benefits of psychedelic-assisted therapy, (2) best practices associated with the delivery of psychedelic-assisted therapy, and (3) responsible integration of this...
Frontiers in Psychiatry 2022 Charles L. Raison, Rakesh Jain, Andrew Penn et al. 75 citations
Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel examination of associations between amount of psychedelic use and behavioral outcomes, as well as frequency of harms ascribed to psychedelic use. A...
Journal of Affective Disorders Reports September 22, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. 33 citations
Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However,...
AJN, American Journal of Nursing May 16, 2021 Andrew Penn, Caroline Dorsen, Stephanie Hope et al. 40 citations
Psychedelics are a class of psychoactive substances that were studied extensively between 1943 and 1970 as potential therapies for treating a host of mental health disorders, including addiction. Despite promising early results, U.S. psychedelic research was halted in the early 1970s with the enactment of the Controlled Substances Act. As the field of psychedelic-assisted therapy develops,...
Bipolar Disorders May 2, 2021 H. Hendin, Andrew Penn
NT is a 21-year-old female identifying woman who came to the office of her outpatient psychiatric provider a month after a hospitalization for a brief psychotic episode, later diagnosed as mania, that she believes was triggered by consuming a substantial amount of psilocybe cubensis mushrooms that she had taken recreationally. While she has a positive family history (father and paternal...
Journal of Humanistic Psychology April 23, 2021 Andrew Penn, Janis Phelps, William E Rosa et al. 37 citations
Psychedelic therapies intentionally combine a caring/healing environment, psychotherapy, and psychedelic medicine as a powerful means of treating intractable conditions of depression and posttraumatic stress disorder. This article utilizes the nursing theory of human caring science, as articulated by Jean Watson, to describe the essential and fundamental human caring qualities in psychedelic...
medRxiv April 7, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. preprint
Abstract Objective: Given the treatment limitations of depression in bipolar disorder, we evaluated the known risks of using psilocybin (and similar substances) in this population, including a systematic assessment of published case histories, to assess the risk of psilocybin as a treatment of depression in bipolar disorder. Data Sources: A comprehensive search of case studies published through...
Journal of Palliative Medicine September 22, 2020 William E Rosa, Caroline Dorsen, Andrew Penn
We applaud the findings of Beaussant and colleagues 1 in defining the research priorities for psychedelic-assisted therapies in palliative care. The innovative conceptual framework posed for integrating these therapies into extant care delivery models promotes the strategic use of psychedelic-assisted interventions capable of reaching those patients most in need. A recent scoping review of...
Journal of Psychosocial Nursing and Mental Health Services September 1, 2019 Andrew Penn
The increasing public acceptance of cannabis and the proliferation of cannabis products in the marketplace has coincided with more patients using the drug as a substitute for psychiatric medications or as an adjunctive treatment modality for psychiatric conditions, despite limited evidence of efficacy. With a goal of furthering harm-reduction efforts in psychiatric nursing, the current article...